Wrinkles Clinical Trial
Official title:
Phase 4 Study - A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines
NCT number | NCT01267149 |
Other study ID # | PRV-2010 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | December 23, 2010 |
Last updated | December 27, 2010 |
Start date | August 2010 |
Statistical Hypotheses The Null Hypothesis: There is no difference in the reduction of lines
in the treated areas as compared to baseline.
Alternative Hypothesis: There is a difference in the reduction of lines in the treated areas
as compared to baseline.
Status | Recruiting |
Enrollment | 13 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 35 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Females and males in good general health between 35 to 65 years of age. - Must be willing to give and sign a HIPPA form, informed consent form and a photographic release form - Patient is planning to undergo Prevelle Silk treatment - A potential subject's must exhibit: A. moderate to severe superficial, vertical perioral and horizontal canthus lines - For FEMALE PATIENT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the patient become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation - Negative urine pregnancy test results at the time of study entry (if applicable) - Must be willing to comply with study regimen and complete the entire course of the study. Exclusion Criteria: - A patient with any UNCONTROLLED systemic disease. A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study - A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study. - A patient with a known hypersensitivity to any of the components of the study medications - A patient who is actively smoking or plans to smoke at any time of the duration of this study - A patient with an active skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis, herpes labialis) - A patient planning any other cosmetic procedure to their facial area during the study period, other than the treatments that will be performed by the investigator - A patient using any topical (prescription or over the counter) medicated creams, lotions, gels, balms, powders, etc. on the treatment areas during the study period - A patient receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral or lateral canthal areas within 7 days prior to or during the study period, other than the study products - A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their perioral or lateral canthal areas within 30 days prior to or during the study period - A patient using any topical tretinoin product or derivative on their perioral or lateral canthal areas within 12 weeks prior to or during the study period - A patient receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their perioral or lateral canthal areas must have discontinued the drug/treatment and/or had the procedure at least 6 months prior to entering the study - A patient that has previously been treated with botulinum toxin in the perioral or lateral canthal areas within the past six months - A patient that has previously been treated with dermal filler in the perioral or lateral canthal areas within the past year - A patient that with a history of allergic reaction to a dermal filler or lidocaine - A patient that with a history of a permanent filler to the perioral or lateral canthal areas - A female patient who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)] - Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | Goldman, Butterwick, Fitzpatrick and Groff | La Jolla | California |
United States | The Maas Clinic | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Goldman, Butterwick, Fitzpatrick and Groff | Mentor Worldwide, LLC |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01984619 -
Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles
|
N/A | |
Completed |
NCT01713985 -
Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck
|
N/A | |
Recruiting |
NCT01586819 -
Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A
|
Phase 3 | |
Completed |
NCT05254210 -
Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device
|
N/A | |
Completed |
NCT02604641 -
Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin
|
N/A | |
Completed |
NCT01460927 -
TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides
|
N/A | |
Completed |
NCT01519934 -
A Retrospective Study to Evaluate the Effectiveness of the Ulthera System
|
N/A | |
Completed |
NCT03811756 -
The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters
|
N/A | |
Completed |
NCT04988412 -
The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters
|
N/A | |
Completed |
NCT02913547 -
Silk'n HST for Wrinkle Reduction - Clinical Study Protocol
|
N/A | |
Active, not recruiting |
NCT02019004 -
A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles
|
N/A | |
Completed |
NCT02340078 -
A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection
|
N/A | |
Completed |
NCT01283464 -
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
|
Phase 2 | |
Completed |
NCT01034956 -
Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections
|
N/A | |
Completed |
NCT02425943 -
Sculptra Aesthetic Post-Approval Study
|
Phase 4 | |
Recruiting |
NCT05847530 -
Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions
|
N/A | |
Enrolling by invitation |
NCT01847066 -
Epidermal Delivery of Ani-Aging Ingredients
|
N/A | |
Completed |
NCT01859611 -
TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides
|
N/A | |
Completed |
NCT01297634 -
Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle
|
Phase 4 | |
Completed |
NCT05011461 -
The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles
|
N/A |